The abstract is read at the publisher; the summary is JClub's.
In a murine orthotopic HCC model, partial hepatectomy abolishes adjuvant anti-PD-1 efficacy (p =0.0084) while neoadjuvant anti-PD-1 reduces tumor burden (p =0.0005).
- Why it matters: Perioperative use of immune checkpoint inhibitors in HCC is not well defined, and surgery may reshape the tumor microenvironment in ways that alter treatment response.
- What they did: Mice underwent noncurative partial hepatectomy with anti-PD-1 given as neoadjuvant or adjuvant, and a separate curative hepatectomy experiment assessed recurrence and survival; effector T-cell infiltration, exhaustion markers (TIM-3, LAG-3), and myeloid-derived suppressor cells were measured.
- The result: Adjuvant anti-PD-1 reduced efficacy in the adjuvant setting, linked to fewer effector memory CD103+ CD8+ T cells, higher TIM-3 and LAG-3, and more myeloid-derived suppressor cells; myeloid-derived suppressor cell depletion (p =0.0084) and delayed dosing partially rescued responses, whereas neoadjuvant therapy lowered recurrence (35% vs. 68%, p =0.0405) and improved survival (p =0.0373).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.